News

The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase (ROCK) that are important to the therapeutic application of human induced pluripotent stem cells

The trial is being carried out at the Hadassah-Hebrew University Medical Center in Jerusalem, Israel by Dr. Itai Berger, director of Neuro-Cognitive Center, and the principal investigator of

The company is developing Mydicar as a new first-in-class therapy for patients with chronic heart failure due to systolic dysfunction. The drug uses genetic enzyme replacement therapy to

Zertane is an oral drug currently in late-stage development as a proprietary treatment for premature ejaculation, a condition that has a major impact on the quality of life

BrainStorm Cell Therapeutics’ new US patent covers the production method of its proprietary stem cells induced to secrete significantly elevated levels of neurotrophic factors for the treatment of

These cell banks are necessary steps in the production of the cells to be encapsulated using the cell-in-a-Box technology for Nuvilex’s Phase IIb clinical trials in advanced, inoperable

Xencor president and CEO Dr Bassil Dahiyat noted that Merck’s program is the sixth drug candidate using our XmAb intellectual property currently in clinical trials and is the

The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase (ROCK) that are crucial to the therapeutic application of human induced pluripotent stem cells

Duodopa is approved in Canada for the management of advanced Parkinson’s disease in adults with severe, disabling motor fluctuations and hyper-/dyskinesia (involuntary movements) not satisfactorily controlled by combinations